New drug aims to calm stubborn hives triggered by cold or scratching
NCT ID NCT07181369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 participants will take part, with some receiving the drug and others a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INDUCIBLE URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organization gmbh
RECRUITINGBerlin, Germany
Contact Email: •••••@•••••
-
Fraunhofer Institute For Translational Medicine And Pharmacology
NOT_YET_RECRUITINGBerlin, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children